SCHEMBL3227940

SCHEMBL3227940

CCCCCCCCCC=CC=CC=CC=CC=CC(=O)O.CCCCCCCCCCCC=CC=CC=CC=CC=CC(=O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.65
FASN P49327 1/20 0.65
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.57
TSHR P16473 1/20 0.57
CNR1 P21554 2/20 0.55
CNR2 P34972 2/20 0.55
FAAH O00519 2/20 0.54
GMNN O75496 1/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX15 P16050 1/20 0.53
APEX1 P27695 1/20 0.53
CYP2C19 P33261 1/20 0.53
RECQL P46063 1/20 0.53
BLM P54132 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10977120 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL15440591 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL8403803 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL10980307 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL18185437 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL296231 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL7121862 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL22749030 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL20499878 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR
SCHEMBL14858316 1.00 PTPN1 (0.65) PTPN1FASNKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090269828-A1 ACYLTRANSFERASES FOR ALTERATION OF POLYUNSATURATED FATTY ACIDS AND OIL CONTENT IN OLEAGINOUS YEASTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-10-29 US claimed
US-20070054385-A1 Acyltransferases for alteration of polyunsaturated fatty acids and oil content in oleaginous yeasts YADAV NARENDRA S 2007-03-08 US claimed
US-20060160193-A1 Acyltransferases for alteration of polyunsaturated fatty acids and oil content in oleaginous yeasts E. I. DU PONT DE NEMOURS AND COMPANY 2006-07-20 US claimed
EP-1664320-A2 ACYLTRANSFERASES FOR ALTERATION OF POLYUNSATURATED FATTY ACIDS AND OIL CONTENT IN OLEAGINOUS YEASTS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-06-07 EP claimed
WO-2006052814-A2 A MORTIERELLA ALPINA DIACYLGLYCEROL ACYLTRANSFERASE FOR ALTERATION OF POLYUNSATURATED FATTY ACIDS AND OIL CONTENT IN OLEAGINOUS ORGANISMS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-05-18 WO claimed
US-20060094087-A1 Mortierella alpina diacylglycerol acyltransferase for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms DUPONT US HOLDING, LLC 2006-05-04 US claimed
WO-2005003322-A2 ACYLTRANSFERASES FOR ALTERATION OF POLYUNSATURATED FATTY ACIDS AND OIL CONTENT IN OLEAGINOUS YEASTS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2005-01-13 WO claimed
US-20200236983-A1 COMPOSITIONS AND METHODS FOR INCREASING MITOCHONDRIAL ACTIVITY CORR-JENSEN INC. 2020-07-30 US disclosed
US-20190201350-A1 TIME RELEASE OF FAT-SOLUBLE ACTIVES CORR-JENSEN INC. 2019-07-04 US disclosed
US-20190183815-A1 TIME RELEASE OF CoQ10 CORR-JENSEN INC. 2019-06-20 US disclosed
US-20180368458-A1 TIME RELEASE VITAMINS AND MINERALS IN EDIBLE OILS CORR-JENSEN INC. 2018-12-27 US disclosed
EP-3416494-A1 TIME RELEASE VITAMINS AND MINERALS IN EDIBLE OILS Corr-Jensen Inc. (US) 2018-12-26 EP disclosed
WO-2018035030-A1 TIME RELEASE FAT-SOLUBLE ACTIVES CORR-JENSEN INC. (US) 2018-02-22 WO disclosed
EP-1901613-A1 NUTRACEUTICAL COMPOSITION FOR IMPROVING FOOTPAD&COAT AND SKIN QUALITY IN PETS DSMIP Assets B.V. (NL) 2008-03-26 EP disclosed
WO-2007006471-A1 NUTRACEUTICAL COMPOSITION FOR IMPROVING FOOTPAD & COAT AND SKIN QUALITY IN PETS DSM IP ASSETS B.V. (NL) 2007-01-18 WO disclosed
EP-1282367-B1 EGGS WITH BALANCED LIPID COMPOSITION BELOVO EGG SCIENCE AND TECHNOL (BE) 2005-11-02 EP disclosed
US-20040022924-A1 Eggs with balanced lipid composition COOPERATIEVE RABOBANK U.A., NEW YORK BRANCH, AS ADMINISTRATIVE AGENT 2004-02-05 US disclosed
EP-1282367-A1 EGGS WITH BALANCED LIPID COMPOSITION Belovo, Egg Science and Technology (BE) 2003-02-12 EP disclosed
WO-2001087091-A1 EGGS WITH BALANCED LIPID COMPOSITION BELOVO (BE) 2001-11-22 WO disclosed
EP-1155627-A1 Eggs with balanced lipid composition Belovo Eggs & Egg Products (BE) 2001-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190201350-A1 TIME RELEASE OF FAT-SOLUBLE ACTIVES FABP4, LIPC, CEL PTPN1 1533/4885FASN 79/4885KDM4E 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.